Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Packard, C
Right arrow Search for Related Content
PubMed
Right arrow Articles by Packard, C
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The European Society of Cardiology

Improving outcomes through statin therapy – a review of ongoing trials

C Packard*

University of Glasgow, Glasgow, Scotland, UK

* Chris Packard, DSc, FRSE, Professor of Pathological Biochemistry, Department of Pathological Biochemistry, Glassgow Royal Infirmatry, University Block, 10 Alexandra Parade, Glasgow G31 2ER, UK. Tel: +44-141-211-4979/+44(0)141-211-4322; fax: +44-141-553-2558
chris.packard{at}clinmed.gla.ac.uk

Abstract

Statin treatment reduces cardiovascular risk in a wide variety of patients. Ongoing studies seek to define better the full range of benefits of such treatment. The issue of how far low-density lipoprotein cholesterol should be lowered for optimal reduction of coronary heart disease risk is being assessed in the TNT, IDEAL and SEARCH trials. The relationships among statin treatment, cardiovascular outcomes and levels of the inflammatory marker C-reactive protein are being assessed in the PROVE-IT and JUPITER trials. Mechanisms for the effects of statin treatment in preventing recurrent events when given early after occurrence of acute coronary syndromes are being examined in the LUNAR trial. The potential benefits of statin therapy in the setting of chronic heart failure are being evaluated in the CORONA, GISSI-HF and UNIVERSE trials. The results of these trials will provide important information on how to maximise the therapeutic benefits of statins in a broader range of patients at risk for cardiovascular morbidity and mortality.

Key Words: Statins • Cardiovascular disease • C-reactive protein • Acute coronary syndromes • LDL cholesterol • Coronary heart disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.